Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.

<h4>Background</h4>A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009-2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Marta Valenciano, Esther Kissling, Jean-Marie Cohen, Beatrix Oroszi, Anne-Sophie Barret, Caterina Rizzo, Baltazar Nunes, Daniela Pitigoi, Amparro Larrauri Cámara, Anne Mosnier, Judith K Horvath, Joan O'Donnell, Antonino Bella, Raquel Guiomar, Emilia Lupulescu, Camelia Savulescu, Bruno C Ciancio, Piotr Kramarz, Alain Moren
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2011
Materias:
R
Acceso en línea:https://doaj.org/article/0f23629a956346d0b90c7cb1b96c8530
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0f23629a956346d0b90c7cb1b96c8530
record_format dspace
spelling oai:doaj.org-article:0f23629a956346d0b90c7cb1b96c85302021-11-18T05:41:58ZEstimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.1549-12771549-167610.1371/journal.pmed.1000388https://doaj.org/article/0f23629a956346d0b90c7cb1b96c85302011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21379316/pdf/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009-2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1).<h4>Methods and findings</h4>Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study patients meeting the European ILI case definition with onset of symptoms >14 days after the start of national pandemic vaccination campaigns. We compared pH1N1 cases to influenza laboratory-negative controls. A valid vaccination corresponded to >14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis excluding individuals with missing values and a multiple multivariate imputation to estimate missing values. The multivariate imputation (n = 2902) adjusted pandemic VE (PIVE) estimates were 71.9% (95% confidence interval [CI] 45.6-85.5) overall; 78.4% (95% CI 54.4-89.8) in patients <65 years; and 72.9% (95% CI 39.8-87.8) in individuals without chronic disease. The complete case (n = 1,502) adjusted PIVE were 66.0% (95% CI 23.9-84.8), 71.3% (95% CI 29.1-88.4), and 70.2% (95% CI 19.4-89.0), respectively. The adjusted PIVE was 66.0% (95% CI -69.9 to 93.2) if vaccinated 8-14 days before ILI onset. The adjusted 2009-2010 seasonal influenza VE was 9.9% (95% CI -65.2 to 50.9).<h4>Conclusions</h4>Our results suggest good protection of the pandemic monovalent vaccine against medically attended pH1N1 and no effect of the 2009-2010 seasonal influenza vaccine. However, the late availability of the pandemic vaccine and subsequent limited coverage with this vaccine hampered our ability to study vaccine benefits during the outbreak period. Future studies should include estimation of the effectiveness of the new trivalent vaccine in the upcoming 2010-2011 season, when vaccination will occur before the influenza season starts.Marta ValencianoEsther KisslingJean-Marie CohenBeatrix OrosziAnne-Sophie BarretCaterina RizzoBaltazar NunesDaniela PitigoiAmparro Larrauri CámaraAnne MosnierJudith K HorvathJoan O'DonnellAntonino BellaRaquel GuiomarEmilia LupulescuCamelia SavulescuBruno C CiancioPiotr KramarzAlain MorenPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 8, Iss 1, p e1000388 (2011)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
spellingShingle Medicine
R
Marta Valenciano
Esther Kissling
Jean-Marie Cohen
Beatrix Oroszi
Anne-Sophie Barret
Caterina Rizzo
Baltazar Nunes
Daniela Pitigoi
Amparro Larrauri Cámara
Anne Mosnier
Judith K Horvath
Joan O'Donnell
Antonino Bella
Raquel Guiomar
Emilia Lupulescu
Camelia Savulescu
Bruno C Ciancio
Piotr Kramarz
Alain Moren
Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.
description <h4>Background</h4>A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009-2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1).<h4>Methods and findings</h4>Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study patients meeting the European ILI case definition with onset of symptoms >14 days after the start of national pandemic vaccination campaigns. We compared pH1N1 cases to influenza laboratory-negative controls. A valid vaccination corresponded to >14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis excluding individuals with missing values and a multiple multivariate imputation to estimate missing values. The multivariate imputation (n = 2902) adjusted pandemic VE (PIVE) estimates were 71.9% (95% confidence interval [CI] 45.6-85.5) overall; 78.4% (95% CI 54.4-89.8) in patients <65 years; and 72.9% (95% CI 39.8-87.8) in individuals without chronic disease. The complete case (n = 1,502) adjusted PIVE were 66.0% (95% CI 23.9-84.8), 71.3% (95% CI 29.1-88.4), and 70.2% (95% CI 19.4-89.0), respectively. The adjusted PIVE was 66.0% (95% CI -69.9 to 93.2) if vaccinated 8-14 days before ILI onset. The adjusted 2009-2010 seasonal influenza VE was 9.9% (95% CI -65.2 to 50.9).<h4>Conclusions</h4>Our results suggest good protection of the pandemic monovalent vaccine against medically attended pH1N1 and no effect of the 2009-2010 seasonal influenza vaccine. However, the late availability of the pandemic vaccine and subsequent limited coverage with this vaccine hampered our ability to study vaccine benefits during the outbreak period. Future studies should include estimation of the effectiveness of the new trivalent vaccine in the upcoming 2010-2011 season, when vaccination will occur before the influenza season starts.
format article
author Marta Valenciano
Esther Kissling
Jean-Marie Cohen
Beatrix Oroszi
Anne-Sophie Barret
Caterina Rizzo
Baltazar Nunes
Daniela Pitigoi
Amparro Larrauri Cámara
Anne Mosnier
Judith K Horvath
Joan O'Donnell
Antonino Bella
Raquel Guiomar
Emilia Lupulescu
Camelia Savulescu
Bruno C Ciancio
Piotr Kramarz
Alain Moren
author_facet Marta Valenciano
Esther Kissling
Jean-Marie Cohen
Beatrix Oroszi
Anne-Sophie Barret
Caterina Rizzo
Baltazar Nunes
Daniela Pitigoi
Amparro Larrauri Cámara
Anne Mosnier
Judith K Horvath
Joan O'Donnell
Antonino Bella
Raquel Guiomar
Emilia Lupulescu
Camelia Savulescu
Bruno C Ciancio
Piotr Kramarz
Alain Moren
author_sort Marta Valenciano
title Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.
title_short Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.
title_full Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.
title_fullStr Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.
title_full_unstemmed Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.
title_sort estimates of pandemic influenza vaccine effectiveness in europe, 2009-2010: results of influenza monitoring vaccine effectiveness in europe (i-move) multicentre case-control study.
publisher Public Library of Science (PLoS)
publishDate 2011
url https://doaj.org/article/0f23629a956346d0b90c7cb1b96c8530
work_keys_str_mv AT martavalenciano estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT estherkissling estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT jeanmariecohen estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT beatrixoroszi estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT annesophiebarret estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT caterinarizzo estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT baltazarnunes estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT danielapitigoi estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT amparrolarrauricamara estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT annemosnier estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT judithkhorvath estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT joanodonnell estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT antoninobella estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT raquelguiomar estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT emilialupulescu estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT cameliasavulescu estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT brunocciancio estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT piotrkramarz estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
AT alainmoren estimatesofpandemicinfluenzavaccineeffectivenessineurope20092010resultsofinfluenzamonitoringvaccineeffectivenessineuropeimovemulticentrecasecontrolstudy
_version_ 1718424833474166784